Veracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.41), $0.26 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $90.1 million versus the consensus estimate of $84.36 million.

GUIDANCE:

Veracyte sees FY2023 revenue of $352-354 million, versus the consensus of $347 million.

For earnings history and earnings-related data on Veracyte (VCYT) click here.